← Back to patent-cliff list
RX-608
Tier C — Watch / tradeRX-608
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Glioma, Solid tumour
Regional status
US
-
EU
-
China
Phase II
2026-09-20
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RX-608?
Approved indications include: Glioma, Solid tumour.
When does the RX-608 patent expire?
No public expiry year is available for RX-608 yet; this page updates once verified.
How do I get a quote for RX-608 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-28